Evidence map›Paper›PMID 37649926›Full record

ReviewCureus2023

Advances and Opportunities in Nanoparticle Drug Delivery for Central Nervous System Disorders: A Review of Current Advances.

Chukwuyem Ekhator, Muhammad Qasim Qureshi, Abdul Wasay Zuberi, Muqaddas Hussain, Niraj Sangroula, Sushanth Yerra, Monika Devi, Muhammad Arsal Naseem, Sophia B Bellegarde, Praful R Pendyala

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chukwuyem EkhatorNeuro-Oncology, New York Institute of Technology, College of Osteopathic Medicine, Old Westbury, USA.
Muhammad Qasim QureshiMedicine and Surgery, Mayo Hospital, Lahore, PAK.
Abdul Wasay ZuberiMedicine and Surgery, Dow University of Health Sciences, Karachi, PAK.
Muqaddas HussainInternal Medicine, Mayo Hospital, Lahore, PAK.
Niraj SangroulaPsychiatry, College of Medical Scieces, Bharatpur, NPL.
Sushanth YerraInternal Medicine, University of Medicine and Health Sciences, Basseterre, KNA.
Monika DeviMedicine, Ziauddin University, Karachi, PAK.
Muhammad Arsal NaseemMedicine, Mayo Hospital, Lahore, PAK.
Sophia B BellegardePathology and Laboratory Medicine, American University of Antigua, St. John's, ATG.
Praful R PendyalaNeurology, Chalmeda Anand Rao Institute of Medical Sciences, Karimnagar, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This narrative review provides an overview of the current advances, challenges, and opportunities in nanoparticle drug delivery for central nervous system (CNS) disorders. The treatment of central nervous system disorders is challenging due to the blood-brain barrier (BBB), which limits the delivery of therapeutic agents to the brain. Promising approaches to address these issues and improve the efficacy of CNS disease therapies are provided by nanoparticle-based drug delivery systems. Nanoparticles, such as liposomes, polymeric nanoparticles, dendrimers, and solid lipid nanoparticles, can be modified to enhance targeting, stability, and drug-release patterns. They allow for the encapsulation of a variety of therapeutic compounds and can be functionalized with ligands or antibodies for active targeting, minimizing off-target effects. Additionally, nanoparticles can circumvent drug resistance processes and provide versatile platforms for applications that combine therapeutic and diagnostic functions. Although the delivery of CNS medications using nanoparticles has advanced significantly, there are still challenges to be resolved. These include understanding the BBB interactions, doing long-term safety studies, and scaling up the production. However, improvements in nanotechnology and a deeper comprehension of CNS disorders provide opportunities to enhance treatment results and address unmet medical requirements. Future research and ongoing clinical trials are required to further explore the potential of nanoparticle drug delivery for CNS disorders.

Indexed as

cns disordersnanoparticlenanotechnologyneurologytargeted therapy

Identifiers

PMID37649926
PMCPMC10463100

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.